Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
The American Journal of Managed Care13 天
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or ...
Business Insider1 个月
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...